Not Yet RecruitingPhase 2

Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD

United States30 participantsStarted 2026-10-01

Plain-language summary

The purpose of this study is to assess the therapeutic efficacy of mosunetuzumab, a bispecific antibody targeting CD20 and CD3 in patients who have detectable chronic lymphocytic leukemia (CLL) after receiving Bruton's tyrosine kinase inhibitors (BTKis) for at least 6 months and have no clinical or laboratory evidence of disease progression.

Who can participate

Age range80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years at the time of signing the Informed Consent Form
✓. Ability to comply with the study protocol and procedures and required
✓. Patients must have received ≥2 prior lines of systemic therapy, including the current BTKi
✓. Patients with high-risk CLL/SLL defined as the presence of any of the following factors:

Exclusion criteria

✕. Patients with high disease burden, defined as having either absolute lymphocyte count \>5 x 109 cells/L, or largest lymph node \>2 cm, or bone marrow with \>50% CLL involvement
✕. Pregnant or breastfeeding or intending to become pregnant during the study or within 3 months after the final dose of mosunetuzumab and tocilizumab (if applicable). Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment. If a serum pregnancy test has not been performed within 14 days prior to receiving first study treatment, a negative urine pregnancy test result (performed within 7 days prior to study treatment) must be available.

What they're measuring

Safety and Adverse Events (AEs)

Timeframe: Through study completion; an average of 1 year

Trial details

NCT IDNCT07566364

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-10-31

Contact for this trial

Mahesh Swaminathan, MBBS

(832) 728-8778 mswaminathan@mdanderson.org

View on ClinicalTrials.gov More Lymphocytic Leukemia trials